Cipla Ltd - Company Profile
Powered by 
All the sales intelligence you need on Cipla Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cipla Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cipla Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cipla Ltd (Cipla) manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological, and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women's health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices and conducts research and development to develop new medicines and drug delivery systems. The company has operations in India, the US, Canada and South Africa among others. Cipla is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra, 400013
Website
www.cipla.com
Telephone
91 22 41916000
No of Employees
31,369
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CIPLA (NSE)
Revenue (2025)
$3.2B
2.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-26.4%
(2025 vs 2024)
Market Cap*
$12.1B
Net Profit Margin (2025)
XYZ
-28.1%
(2025 vs 2024)
* As of and is in US$
Cipla Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Therapies Areas: | Cipla |
| Cardiovascular | Cippoint |
| Dermatology | Synchrobreathe |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Others | In August, the company provided an update regarding the inspection conducted by the United States Food and Drug Administration at the InvaGen Pharmaceuticals Inc. manufacturing facility in Central Islip, Long Island, New York, the US. |
| 2026 | Regulatory Approval | In July, the company received regulatory approval from U.S. Food and Drug Administration for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg. |
| 2026 | Corporate Changes/Expansions | In June, the company launched the first-of-its-kind Sputum Inflammometry Lab at the Breathefree Lung Wellness Center (BLWC) in Mumbai. |
Competitor Comparison
| Key Parameters | Cipla Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Aurobindo Pharma Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Hyderabad | Mumbai |
| State/Province | Maharashtra | Maharashtra | Telangana | Telangana | Maharashtra |
| No. of Employees | 31,369 | 47,000 | 27,527 | 29,209 | 26,021 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Achin Gupta | Managing Director; Director; Chief Executive Officer - Global | Executive Board | 2026 | - |
| Ashish Adukia | Chief Financial Officer | Senior Management | 2022 | - |
| Sneha Hiranandani | Chief Information Officer | Senior Management | 2013 | - |
| Arun Kakatkar | Chief People Officer | Senior Management | 2026 | - |
| Prabhakaran Nair | Chief Manufacturing Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer